Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study

Cancer. 1986 Aug 15;58(4):865-72. doi: 10.1002/1097-0142(19860815)58:4<865::aid-cncr2820580411>;2-s.


To evaluate the clinical effects of the anti-tumor polysaccharide Schizophyllan (SPG), a randomized study was done on 220 patients with Stage II or Stage III cervical cancer who had been given irradiation, concomitantly. The tumor-reducing effect of SPG was significant in patients in either stage. The time to recurrence was longer in SPG-dosed patients with Stage II cancer, compared with findings in the control group. There was no significant difference in the time to recurrence in patients with Stage III cancer between the SPG and control groups. When comparing the 48-month survival curve, the survival time of patients with Stage II cancer in the SPG group was significantly longer than in the control group. However, there was no significant difference in the survival rate of patients with Stage III cancer between the SPG-dosed and control groups.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Actuarial Analysis
  • Aged
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Glycosaminoglycans / therapeutic use*
  • Humans
  • Leukocyte Count
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Random Allocation
  • Sizofiran / adverse effects
  • Sizofiran / therapeutic use*
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / radiotherapy


  • Glycosaminoglycans
  • Sizofiran